Vanguard Group
TVTX icon

Vanguard Group’s Travere Therapeutics TVTX Stock Holding History

Vanguard Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$241M Sell
6,309,229
-304,139
-5% -$9.89M ﹤0.01% 1449
2025
Q3 		$158M Buy
6,613,368
+619,085
+10% +$11.6M ﹤0.01% 1667
2025
Q2 		$88.7M Buy
5,994,283
+980,263
+20% +$16.2M ﹤0.01% 1878
2025
Q1 		$89.9M Sell
5,014,020
-1,728,145
-26% -$35.1M ﹤0.01% 1842
2024
Q4 		$117M Sell
6,742,165
-159,985
-2% -$2.83M ﹤0.01% 1802
2024
Q3 		$96.6M Buy
6,902,150
+282,394
+4% +$2.94M ﹤0.01% 1886
2024
Q2 		$54.4M Buy
6,619,756
+353,927
+6% +$2.38M ﹤0.01% 2113
2024
Q1 		$48.3M Buy
6,265,829
+750,686
+14% +$6.33M ﹤0.01% 2183
2023
Q4 		$49.6M Buy
5,515,143
+847,685
+18% +$6.17M ﹤0.01% 2192
2023
Q3 		$41.7M Buy
4,667,458
+460,176
+11% +$6.49M ﹤0.01% 2214
2023
Q2 		$64.6M Buy
4,207,282
+222,688
+6% +$4.05M ﹤0.01% 2077
2023
Q1 		$89.6M Buy
3,984,594
+469,148
+13% +$9.97M ﹤0.01% 1880
2022
Q4 		$73.9M Buy
3,515,446
+133,836
+4% +$2.84M ﹤0.01% 1971
2022
Q3 		$83.3M Buy
3,381,610
+50,791
+2% +$1.31M ﹤0.01% 1908
2022
Q2 		$80.7M Sell
3,330,819
-516,716
-13% -$13M ﹤0.01% 1945
2022
Q1 		$99.2M Sell
3,847,535
-33,338
-0.9% -$885K ﹤0.01% 1945
2021
Q4 		$120M Buy
3,880,873
+15,392
+0.4% +$433K ﹤0.01% 1888
2021
Q3 		$93.7M Buy
3,865,481
+30,725
+0.8% +$565K ﹤0.01% 2010
2021
Q2 		$55.9M Sell
3,834,756
-166,832
-4% -$3.29M ﹤0.01% 2311
2021
Q1 		$99.9M Buy
4,001,588
+597,145
+18% +$16.5M ﹤0.01% 1947
2020
Q4 		$92.8M Buy
3,404,443
+181,611
+6% +$4.24M ﹤0.01% 1858
2020
Q3 		$59.5M Buy
3,222,832
+251,988
+8% +$4.9M ﹤0.01% 1918
2020
Q2 		$60.6M Buy
2,970,844
+396,250
+15% +$6.31M ﹤0.01% 1910
2020
Q1 		$37.6M Buy
2,574,594
+51,259
+2% +$771K ﹤0.01% 1992
2019
Q4 		$35.8M Buy
2,523,335
+156,639
+7% +$2M ﹤0.01% 2253
2019
Q3 		$27.4M Buy
2,366,696
+174,694
+8% +$2.89M ﹤0.01% 2323
2019
Q2 		$44M Buy
2,192,002
+73,736
+3% +$1.46M ﹤0.01% 2173
2019
Q1 		$47.9M Buy
2,118,266
+91,878
+5% +$2.03M ﹤0.01% 2105
2018
Q4 		$45.9M Buy
2,026,388
+97,786
+5% +$2.43M ﹤0.01% 2067
2018
Q3 		$55.4M Buy
1,928,602
+26,016
+1% +$744K ﹤0.01% 2094
2018
Q2 		$51.9M Buy
1,902,586
+134,701
+8% +$3.59M ﹤0.01% 2113
2018
Q1 		$39.5M Buy
1,767,885
+64,595
+4% +$1.54M ﹤0.01% 2193
2017
Q4 		$35.9M Buy
1,703,290
+16,446
+1% +$376K ﹤0.01% 2231
2017
Q3 		$42M Buy
1,686,844
+51,610
+3% +$1.14M ﹤0.01% 2126
2017
Q2 		$31.7M Buy
1,635,234
+125,695
+8% +$2.28M ﹤0.01% 2251
2017
Q1 		$27.9M Buy
1,509,539
+102,833
+7% +$2.01M ﹤0.01% 2293
2016
Q4 		$26.6M Buy
1,406,706
+74,223
+6% +$1.52M ﹤0.01% 2285
2016
Q3 		$29.8M Buy
1,332,483
+76,907
+6% +$1.46M ﹤0.01% 2176
2016
Q2 		$22.4M Buy
1,255,576
+69,097
+6% +$1.12M ﹤0.01% 2280
2016
Q1 		$16.2M Buy
1,186,479
+16,028
+1% +$243K ﹤0.01% 2385
2015
Q4 		$22.6M Buy
1,170,451
+19,152
+2% +$383K ﹤0.01% 2259
2015
Q3 		$23.3M Buy
1,151,299
+113,702
+11% +$3.37M ﹤0.01% 2215
2015
Q2 		$34.4M Buy
1,037,597
+316,464
+44% +$8.67M ﹤0.01% 2119
2015
Q1 		$17.3M Buy
721,133
+81,451
+13% +$1.24M ﹤0.01% 2383
2014
Q4 		$7.83M Buy
639,682
+232,663
+57% +$2.41M ﹤0.01% 2653
2014
Q3 		$3.67M Buy
407,019
+81,958
+25% +$964K ﹤0.01% 3000
2014
Q2 		$3.82M Buy
325,061
+49,979
+18% +$677K ﹤0.01% 2981
2014
Q1 		$5.85M Buy
+275,082
New +$4.23M ﹤0.01% 2749

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group's TVTX Position: Q4 2025 in Review

Vanguard Group reduced its Travere Therapeutics (TVTX) stake by 4.6% in Q4 2025, selling an estimated $9.89M and leaving 6,309,229 shares worth $241M. The position accounts for ﹤0.01% of the portfolio, ranked #1449.

Vanguard Group first reported a position in TVTX in Q1 2014 and has held it in 48 quarters since. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Vanguard Group held 6,309,229 shares of Travere Therapeutics worth $241M as of Q4 2025.
  • Vanguard Group sold 304,139 Travere Therapeutics shares in Q4 2025, an estimated $9.89M.
  • Travere Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1449 holding.
  • Vanguard Group first reported a position in Travere Therapeutics in Q1 2014 and has held it in 48 quarters since.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.